| CRDL Stock | | | CAD 1.93 0.10 4.93% |
This module uses fundamental data of Cardiol Therapeutics to approximate its Piotroski F score. Cardiol Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Cardiol Therapeutics Class. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Cardiol Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
As of the 13th of December 2024,
Short and Long Term Debt Total is likely to drop to about 133.9
K. In addition to that,
Net Debt is likely to drop to about (36.4
M). At this time, Cardiol Therapeutics'
Graham Number is very stable compared to the past year. As of the 13th of December 2024,
Shareholders Equity Per Share is likely to grow to 0.64, while
PTB Ratio is likely to drop 2.38.
At this time, it appears that Cardiol Therapeutics' Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Inapplicable
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | |
| Change In Outstending Shares | |
Cardiol Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Cardiol Therapeutics is to make sure Cardiol is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Cardiol Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Cardiol Therapeutics' financial numbers are properly reported.
Cardiol Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Cardiol Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Cardiol Therapeutics in a much-optimized way.
Click cells to compare fundamentals
About Cardiol Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Cardiol Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiol Therapeutics from analyzing Cardiol Therapeutics' financial statements. These drivers represent accounts that assess Cardiol Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiol Therapeutics' important valuation drivers and their relationship over time.
| | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) |
| Market Cap | | 118.3M | 83.0M | 100.7M | 43.1M | 49.6M | 93.1M |
| Enterprise Value | | 111.5M | 69.1M | 16.9M | (16.3M) | (18.7M) | (17.8M) |
About Cardiol Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiol Therapeutics Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiol Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Cardiol Therapeutics Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics'
future performance.
For an informed investment choice regarding Cardiol Stock, refer to the following important reports: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.